invivo mab rat igg2a isotype control (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
98
Structured Review
Bio X Cell
invivo mab rat igg2a isotype control
Invivo Mab Rat Igg2a Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 817 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype+control+igg2a+mab/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/bio_rxiv__64898__2026__03__17__712479-219-9-20
Average 98 stars, based on 817 article reviews
Invivo Mab Rat Igg2a Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 817 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/isotype+control+igg2a+mab/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/bio_rxiv__64898__2026__03__17__712479-219-9-20
Average 98 stars, based on 817 article reviews
invivo mab rat igg2a isotype control - by Bioz Stars,
2026-09
98/100 stars
Images
1) Product Images from "Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma"
Article Title: Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma
Journal: bioRxiv
doi: 10.64898/2026.03.17.712479
Figure Legend Snippet: A , C57/BL6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1), expressing a shRNA targeting ASS1 or a shRNA control. When tumors reached a mean of 100mm3, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control. The data are presented as the mean ± SEM for each group (n=10 mice per group). p-values were calculated using two-way ANOVA. B , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in B. The data are presented as the mean ± SEM (YUMM1.1shCTL n=9 tumors ; YUMM1.1shASS1 n=10 tumors). C , Deconvolution performed using CIBERSORTx performed on tumors from the experiment presented in A. D , Ratio CD8+ cells to malignant cells (Mal.) from the panel C is presented in tumor from the experiment presented in the panel A. E , Representative immunostaining of CD8+ T lymphocytes (red, CD8a) and nuclei (blue, DAPI) on frozen tumor sections of mice from panel A. F, Representation of CD8+ cells shown in D, the data are presented as the mean ± SEM (n=9 tumors). G. Representative immunostaining of CD8+ T cells and granzyme B on frozen tumor sections of mice from panel A.
Techniques Used: Expressing, shRNA, Control, Flow Cytometry, Immunostaining
![A , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line after 3 days of treatment with MDLA. HSP90 serves as a loading control. B , ASS1 enzymatic activity was performed in ICI-resistant YUMM1.1 cell line after 3 days of treatment with (n=3; mean ± SEM). C , Intracellular concentration of arginine was measure in ICI-resistant YUMM1.1 cells after 3 days of treatment with MDLA. (n=3; mean ± SEM). D. Schematic representation of the impact of arginine on the control upstream of mTORC1. E. Immunoprecipaption was performed on WM9 cells transfected with HA-tagged CASTOR1 and cultured for 3 days in the presence of different concentration of arginine and MDLA. Immunoblot showing the expression levels of indicated protein. F , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line. β-actine was use as a loading control. G , Immunoblot showing the expression levels of indicated protein in WM9 melanoma cell line. H , Renilla over Firefly luminescent ratio quantification in ICI-resistant YUMM1.1 cell line. I , Renilla over Firefly luminescent ratio quantification in WM9 melanoma cell line. J , YUMM1.1 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). K , WM9 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). L , Immunoblot showing the expression levels of indicated protein in cells from tumors of patients with metastatic melanoma. HSP90 serves as a loading control. M , Renilla over Firefly luminescent ratio quantification in cells from tumors of patients with metastatic melanoma (n=3; mean ± SEM). N , Cells isolated from tumors of patients with metastatic melanoma were treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). O , C57BL/6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1). When tumors reached a mean of 100mm 3 , mice were treated with MDLA (700mg.kg-1) or PBS, twice a day. Two days after the beginning of the MDLA treatment, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, every two days, 3 times. Mice were treated with an additional dose of anti-PD-1 or isotype IgG control at day 24. Tumor growth was monitored for 27 days. The data representing the tumor growth are presented as the mean ± SEM for each group (n=10 mice per group). p -values were calculated using two-way ANOVA. P , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in P. The data are presented as a ratio of percentage between CD45-positive cells versus CD45-negative cells. (n=10 tumors per group, mean ± SEM). Q , Percentage of CD45 and CD8a-double positive cells in tumors, determined by flow cytometry in tumors presented in P. (n=10 tumors per group, mean ± SEM).](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_79/10__64898_slash_2026__03__17__712479/10__64898_slash_2026__03__17__712479___F6.large.jpg "... mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, every two days, 3 ...")
Figure Legend Snippet: A , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line after 3 days of treatment with MDLA. HSP90 serves as a loading control. B , ASS1 enzymatic activity was performed in ICI-resistant YUMM1.1 cell line after 3 days of treatment with (n=3; mean ± SEM). C , Intracellular concentration of arginine was measure in ICI-resistant YUMM1.1 cells after 3 days of treatment with MDLA. (n=3; mean ± SEM). D. Schematic representation of the impact of arginine on the control upstream of mTORC1. E. Immunoprecipaption was performed on WM9 cells transfected with HA-tagged CASTOR1 and cultured for 3 days in the presence of different concentration of arginine and MDLA. Immunoblot showing the expression levels of indicated protein. F , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line. β-actine was use as a loading control. G , Immunoblot showing the expression levels of indicated protein in WM9 melanoma cell line. H , Renilla over Firefly luminescent ratio quantification in ICI-resistant YUMM1.1 cell line. I , Renilla over Firefly luminescent ratio quantification in WM9 melanoma cell line. J , YUMM1.1 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). K , WM9 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). L , Immunoblot showing the expression levels of indicated protein in cells from tumors of patients with metastatic melanoma. HSP90 serves as a loading control. M , Renilla over Firefly luminescent ratio quantification in cells from tumors of patients with metastatic melanoma (n=3; mean ± SEM). N , Cells isolated from tumors of patients with metastatic melanoma were treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). O , C57BL/6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1). When tumors reached a mean of 100mm 3 , mice were treated with MDLA (700mg.kg-1) or PBS, twice a day. Two days after the beginning of the MDLA treatment, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, every two days, 3 times. Mice were treated with an additional dose of anti-PD-1 or isotype IgG control at day 24. Tumor growth was monitored for 27 days. The data representing the tumor growth are presented as the mean ± SEM for each group (n=10 mice per group). p -values were calculated using two-way ANOVA. P , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in P. The data are presented as a ratio of percentage between CD45-positive cells versus CD45-negative cells. (n=10 tumors per group, mean ± SEM). Q , Percentage of CD45 and CD8a-double positive cells in tumors, determined by flow cytometry in tumors presented in P. (n=10 tumors per group, mean ± SEM).
Techniques Used: Western Blot, Expressing, Control, Activity Assay, Concentration Assay, Transfection, Cell Culture, Positive Control, Isolation, Flow Cytometry
Related Articles
Control:Article Title: Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) Article Snippet: For checkpoint blockade treatment, mice were injected i.p. with 200 μg of PD-1 (clone RMP 1-14, BioXcell) and 200 μg CTLA4 (clone 9H10, BioXcell), starting at days 9 to 14 (therapy start time point), using 7 and 3 doses, respectively. .. Control mice received the Article Title: Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy Article Snippet: For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonist CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free), or the isotype control IgG2a mAb (clone 2A3, BioXcell), and administered 48hrs after chemotherapy administration. .. For checkpoint blockade treatment, mice were injected i.p. with 200 μg of PD-1 (clone RMP 1–14, BioXcell) and 200 μg CTLA4 (clone 9H10, BioXcell), or the Article Title: Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) Article Snippet: .. For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonistic CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free) or the Article Title: Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma Article Snippet: .. Mice were injected intraperitoneally with 200 μg of anti–PD-1 (clone RMP 1–14, BioXcell) and/or 200 μg anti-CTLA-4 (clone 9D9, BioXcell), or the Article Title: Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy Article Snippet: .. For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonist CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free), or the Injection:Article Title: Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy Article Snippet: For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonist CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free), or the isotype control IgG2a mAb (clone 2A3, BioXcell), and administered 48hrs after chemotherapy administration. .. For checkpoint blockade treatment, mice were injected i.p. with 200 μg of PD-1 (clone RMP 1–14, BioXcell) and 200 μg CTLA4 (clone 9H10, BioXcell), or the Article Title: Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) Article Snippet: .. For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonistic CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free) or the Article Title: Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma Article Snippet: .. Mice were injected intraperitoneally with 200 μg of anti–PD-1 (clone RMP 1–14, BioXcell) and/or 200 μg anti-CTLA-4 (clone 9D9, BioXcell), or the Article Title: Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy Article Snippet: .. For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonist CD40 rat anti-mouse IgG2a mAb (clone FGK45, endotoxin-free), or the Mouse Assay:Article Title: Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma Article Snippet: .. Mice were injected intraperitoneally with 200 μg of anti–PD-1 (clone RMP 1–14, BioXcell) and/or 200 μg anti-CTLA-4 (clone 9D9, BioXcell), or the |
![(a) Relative amino acid levels in UFM1 -knockout versus control cells ( n = 3 biologically independent samples). Horizontal dotted lines mark a P value of 0.05 (y-axis). (b) Alanine levels in UFM1 -knockout and control cells (mean ± s.d., n = 3 biologically independent samples). Two-tailed Welch’s t -test. ** P < 0.005, * P < 0.01. (c) Schematic depicting exogenous alanine uptake and de novo synthesis from pyruvate. Most human cancer lines display near-selective expression of GPT2 relative to GPT1 . (d) Schematic depicting the incorporation of 13 C from [U- 13 C] glucose into alanine and lactate. (e, f) Fractional labeling of alanine (e) and pyruvate (f) in UFM1 -knockout and control cells (mean ± s.d., n = 3 biologically independent samples). Two-tailed Welch’s t -test. Values above brackets indicate differences in fractional labeling between bars. (g) Immunoblot for expression of GPT2 in UFM1 -knockout and control cells. ACTN1 served as the loading control. (h) Relative growth of UFM1 -knockout versus control cells (mean ± s.d., n = 3 biologically independent samples). Two-tailed Welch’s t -test comparing the respective mean ± s.d. (bar) versus mean ± s.d. (control cells) between bars. (i) Schematic of RPL26, a component of the 60S subunit. RPL26 is the primary UFMylation substrate and is modified specifically on ER-localized ribosomes. (j, k) Immunoblots for expression of RPL26 (j) and GPT2 (k) in UFSP2 -knockout and control cells. RAPTOR served as the loading control in both cases. (l, m) Immunoblots for expression of GPT2, RPL26 (l) and UFM1 (m) in whole-cell lysates (WC) and GPT2-immunopurified fractions (IP:GPT2) from UFSP2 -knockout cells. <t>IgG</t> isotype control (IP:IgG) served as a negative control. ACTN1 served as the WC loading control. To prevent interference from the IgG heavy chain (∼50-55 kDa) with GPT2 signal (∼58 kDa), a light chain-specific secondary antibody was used for the GPT2 immunoblot. Asterisks in (l) denote non-specific bands. In b and h, values above brackets indicate fold change between bars. In h and j-m, H, HPLM-defined concentration; R, RPMI-defined concentration. In g and k-m, L.B., low brightness; H.B., high brightness.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_30/10__64898_slash_2026__03__27__714830/10__64898_slash_2026__03__27__714830___F2.large.jpg)
